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Abstract: 
Introduction: Both isoproterenol (Iso) and adenosine (Ado) are used to induce atrial 
fibrillation (AF) in the electrophysiology lab. However, the utility of Ado has not been 
systematically established. 
Objective: The purpose of this study was to compare Ado to Iso for the induction of 
paroxysmal AF. 
Methods: Forty patients (16 women, mean age: 60±12 years) with paroxysmal AF, 
presenting for ablation were prospectively included of whom 36 (90%) received Ado 
(18-36 mg) and/or Iso (3-20 µg/min incremental dose) in a randomized order (26 
(72%) received both drugs). 
Results: AF was induced with Iso in 15/32 (47%) and with Ado in 12/30 (40%) 
patients (p=0.9). Iso-triggered AF started from the left pulmonary veins (PVs) in 
11/15 (73%), from the right PVs in 3/15 (20%), from the coronary sinus (CS) in 1/15 
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(7%) cases. Ado-induced AF episodes originated from the left PVs in 6/12 (50%), 
from the right atrium (RA) in 4/12 (33%), from the CS in 2/12 (17%) cases. 
Altogether Iso-induced AF was more likely initiated from the PVs (93%), compared 
to Ado (50%) (p=0.02). Ado-induced non-PV triggers were not predictive of 
arrhythmia recurrence after PV isolation.  
Conclusion: Ado much more frequently induces non-PV triggers, especially from the 
RA. The clinical significance of these foci, however, is questionable.  
Keywords: adenosine, isoproterenol, triggers, atrial fibrillation, pulmonary vein. 
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1. Introduction 
Elimination of initiating triggers has become the cornerstone of atrial fibrillation (AF) 
treatment. Most of these triggers reside in the pulmonary veins (PV) (1); however, 
non-PV triggers are an important source of recurrence after PV isolation. Triggers can 
be identified during the electrophysiology study if spontaneously occurring or can be 
induced by drug challenge. Due to the spurious nature of spontaneous triggers and the 
laboriousness of AF provocation, empirical isolation of all PVs has become the 
standard in AF ablation, despite the fact that selective isolation of only the triggering 
PV can achieve similar success in selected patients (2). Even if total PV isolation is 
pursued as a first step, identification of non-PV triggers gains importance when AF 
occurs despite isolated PVs (3, 4). The role of high dose isoproterenol (Iso) infusion to 
elicit AF triggers is well established (5,6). Besides Iso, adenosine (Ado) or adenosine-
triphosphate (ATP) is increasingly used for the induction of AF, despite the lack of 
systematic studies on the sensitivity and specificity of these drugs. We sought to 
determine the utility of Ado in identifying triggers of paroxysmal AF by comparing it 
to Iso in a prospective, randomized study. 
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2. Methods 
Study Population 
Sample size estimation was based on a previous pilot analysis of retrospective data 
(7). In this, we found marked differences in the location of triggers disclosed by Iso 
and Ado: only PV triggers were induced with Iso, while non-PV triggers were seen in 
88% of those receiving Ado also. Expecting less pronounced a difference: 20% versus 
80% non-PV trigger rate with Iso versus Ado, respectively, and an 80% induction rate 
for both drugs, the sample size for an alpha value of 0.05 and a power of 0.8 would be 
15 patients tested with each drug. Due to dropouts and a lower induction rate during 
the study, altogether 40 patients were enrolled, with the aim being to test at least 30 
patients with each drug. 
All 40 patients (16 women, mean age 60±12 years) had paroxysmal AF, and were 
referred for catheter ablation. The study was approved by the Institutional Review 
Board of the University of Szeged (no. 41-83). All patients gave their written 
informed consent to participate in the study. Exclusion criteria were previous left 
atrial (LA) catheter ablation or open heart surgery, persistent AF, severe valvular heart 
disease or LA thrombus. 
Patients were prospectively included and received Ado and Iso for induction in a 
randomized order. 
Electrophysiologic Procedure 
Patients were on oral anticoagulation for at least 3 weeks before the ablation and all 
antiarrhythmic drugs were discontinued for at least five half-lives except amiodarone, 
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which was discontinued 1 month prior to the procedure. Patients presented in the lab 
in sinus rhythm or in AF for ablation. In case of AF prior to the induction protocol, 
direct current cardioversion (DCCV) was performed. The study was performed under 
light conscious sedation with midazolam ± fentanyl, as described previously (8,9). 
Briefly, after femoral venous access two decapolar steerable catheters (interelectrode 
spacing 2-5-2 mm, Dynamic Deca, Bard Electrophysiology, Lowell, MA, USA) were 
positioned in the coronary sinus (CS) and the posterolateral right atrium with the distal 
pole in the superior vena cava. Double transseptal punctures were performed to access 
the left atrium (LA). Intracardiac echocardiography (ICE) (AcuNav, Acuson Corp., 
Mountain View, CA, USA) was used to guide the transseptal puncture and catheter 
positioning. A decapolar circular mapping catheter (CMC) (Inquiry Optima, St Jude 
Medical, Irvine, CA, USA) was positioned at the left PV antrum overlying both left 
PVs, and a 3.5 mm irrigated-tip mapping catheter (Navistar Thermocool, Biosense 
Webster, Diamond Bar, LA, USA) was positioned on the right PV carina. (Figure 1). 
Drug Challenge 
If the patient presented in AF, DCCV was performed to restore sinus rhythm and 
evaluate for spontaneous re-initiation and identifying post cardioversion AF triggers. 
If the presenting rhythm was sinus or AF was not spontaneously reinitiated after the 
cardioversion, we proceeded with the drug challenge. 
Isoproterenol (Iso) was infused via a short femoral venous sheath in incremental doses 
starting at 3µg/min and increasing after 3-5 minutes to 5 µg/min, 10 µg/min, 
15ug/min, and a maximum dose of 20 µg/min, until induction of AF or intolerable 
side effects occurred. 
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Adenosine (Ado) was administered into the right atrium (RA) via one long transseptal 
sheath that was pulled back in the RA. A quick bolus of 18 mg was given flushed with 
5-10 ml of saline. A second dose of 36 mg was administered if AF was not induced 
after the first dose. Ectopic activity triggering an AF episode was identified and the 
origin determined based on the endocardial activation sequence, as previously 
described (8,9). Triggers of AF were considered to arise from the left PVs if the 
earliest activation and LA-PV electrogram reversal was recorded on the CMC and 
from the right PVs if the earliest atrial activation was recorded on the mapping 
catheter positioned at the right PV carina. If earliest atrial activation during bursts of 
ectopic activity initiating AF was recorded at any of the CS or RA bipoles, then these 
structures were identified as the origin of triggers. (Figure 2) 
The order in which the two drugs were administered (Iso first or Ado first) was 
randomized in a 1:1 fashion. When sustained AF was induced and did not terminate 
after a few minutes, DCCV was performed and the second drug was administered 
after a 5-minute waiting period. In cases when immediate recurrence of AF (IRAF) 
occurred after DCCV, drug challenge was terminated and we proceeded with ablation. 
We determined the effectiveness of the two drugs in inducing AF and compared them 
with each other and spontaneous AF episodes in terms of the location of AF triggers. 
Catheter ablation 
After creation of a 3-dimensional electroanatomic shell of the LA, circumferential, 
irrigated radiofrequency ablation lesions were created around ipsilateral PVs using the 
mapping catheter, with the endpoint of electrical isolation manifested in exit and 
entrance block between LA and PVs. The decision to selectively isolate only the left 
or right PVs - whichever were shown to be arrhythmogenic during drug challenge - or 
 This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
 
empirically isolate all 4 PVs was at the discretion of the operator. However, in case of 
a redo procedure all 4 PVs were isolated, irrespective of the initial approach. 
Statistical Analysis. 
Continuous variables are expressed as mean±SD and compared using Student’s t test. 
The categorical variables are reported as percentage and compared using Chi-square 
analysis. All statistical analyses were performed using the SPSS software version 16 
(IBM Inc., NY, USA). A p<0.05 was considered statistically significant. 
3. Results 
Four (10%) patients could not receive any drug challenge because their spontaneous 
AF ongoing at the commencement of the procedure restarted immediately after 
DCCV. Eighteen of the remaining 36 patients were randomized to receive Iso first and 
18 Ado first. In case of 10 (28%) patients the second drug was not given, because the 
AF induced by the first drug spontaneously restarted after DCCV. Therefore 36 (90%) 
patients received their first and 26/36 (72%) patients the second drug. Altogether 32 
patients received Iso and 30 patients Ado (30 received 18 mg, 21 received 18 and 36 
mg). AF was induced with Iso in 15/32 (47%) and with Ado in 12/30 (40%) patients 
(p=0.9). Iso-triggered AF started from the left PVs in 11 (73%), from the right PVs in 
3 (20%), from the CS in 1 (7%) cases (Figure 3A). Ado-induced AF episodes 
originated from the left PVs in 6 (50%), from the RA in 4 (33%), from the CS in 2 
(17%) cases (Figure 3B). Altogether Iso-induced AF was more likely initiated from 
the PVs (93%), compared to Ado (50%) (p=0.02). 
Of the 26 (72%) patients (Figure 4., Table 1.) who received both drugs, AF could not 
be induced by drug challenge in 13 (50%). Iso triggered AF in 9/26 (35%) patients; all 
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triggers were localized to the PVs (7 left, 2 right PVs). Ado was effective at inducing 
AF in 8/26 (31%), 2 from left PVs and 6 from non-PV sites (4 RA, 2 CS, p<0.01 
versus Iso). Both drugs induced AF in 4/26 (15%) of these cases. In 2 of those 4 
patients triggers originated from the left PVs with both Iso and Ado, while in the 
remaining two cases there was discordance between the two drugs, Ado manifesting 
non-PV triggers. 
Fourteen (35%) patients had spontaneous AF during the procedure, 13 (93%) 
originated from the PVs (9 left, 4 right PVs), and only one from the CS. Ten of these 
cases received one or both drugs. Iso reproduced left or right PV triggers in 6/7 cases 
and was ineffective in one. Ado reproduced left PV triggers in 4/7 cases, but was 
ineffective in 3. This results in a sensitivity to reproduce spontaneous triggers of 86% 
for Iso and 57% for Ado. 
After drug testing 38 of 40 (95%) patients underwent PVI. Two patients – for whom 
initially a selective PVI was planned - did not have an ablation (one was noninducible 
and one had RA trigger on Ado). Thirty of the remaining 38 (79%) received empirical 
isolation of all 4 PVs, while 8 (21%) patients a selective PVI of arrhythmogenic PVs. 
Ten of 38 (26%) underwent a second PVI procedure with the aim of 4-PV isolation, 
because of recurrence of AF. After the last procedure, 32 of 38 (84%) ablated patients 
were free of recurrence during 16±9 months of follow-up. 
Of the 14 patients who had PV triggers disclosed by Iso infusion, one was lost to 
follow-up, and the rest had no AF recurrence after the last PVI. In case of the only 
patient with a non-PV trigger on Iso PVI was ineffective, even after a redo procedure. 
Among the 6 patients with PV triggers on Ado, PVI and redo PVI failed in one. Of the 
6 patients with non-PV triggers on Ado, one was not ablated and one failed PVI and a 
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redo. The remaining 4 are without recurrence after the last procedure. Therefore, 
while Iso was 100% accurate in predicting a favorable response to PVI, the accuracy 
of Ado challenge was only 55%. There was no correlation between non-PV triggers 
induced by Ado and arrhythmia recurrence after the last procedure (p=0.90). 
4. Discussion 
The main finding of this study is that, while Iso mostly induces PV triggers, Ado is 
more likely to induce non-PV triggers of AF, dominantly from the RA. Half of Ado-
inducible patients had AF from non-PV sites, compared with only 7% with Iso. 
Moreover, in two cases the two drugs showed divergent effects in the same patient: 
Ado inducing non-PV, while Iso PV triggers. 
While trigger sites disclosed by Iso challenge showed excellent correlation with the 
long- term response to PVI (no recurrence in case of PV triggers and recurrence in the 
single case of non-PV trigger), there was no such correlation seen with Ado, PVI 
being equally effective in those with PV or non-PV triggers induced by this drug. 
Comparison with previous studies 
The use of Iso in the electrophysiology lab to study triggers of AF is well established 
(5,6,9). It has been shown to effectively identify arrhythmogenic PVs that can 
selectively be ablated, achieving similar success to empirical 4-PV isolation (11). On 
the other hand, Ado has mostly been used anecdotally for AF induction. A number of 
case reports have been published of triggers identified with Ado or ATP, most of 
which originated outside the PVs (12-17). More investigators have used ATP to test 
for non-PV triggers after PVI (18, 19, 20). Strikingly most of these studies originate 
from Asia, utilize ATP, and report a high rate of non-PV triggers (21). 
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Tao et al. (22) used adenosine-triphosphate (ATP) 20 mg for induction in patients 
with paroxysmal or persistent AF. They found that ATP induced AF in 30% of the 
cases and trigger sites were from the PVs in more than 80% of these. The higher rate 
of PV-triggering with ATP compared with our results with Ado may be explained by 
differences in the mode of action and relative doses of the two drugs. The molecular 
weight of ATP is approximately twice that of Ado; therefore, the number of adenosine 
molecules in 20 mg ATP is much less than in 18 mg of Ado, the lower dose in our 
study. On the other hand, ATP exerts a much more pronounced negative chrono- and 
dromotropic response due to its action on P2 receptors located in the left ventricle 
inducing a cardiocardiac vagal reflex (23). The higher relative dose and exclusive 
action on adenosine (P1) receptors may explain the higher rate of RA triggers we saw 
with Ado. 
Nevertheless, another report from Japan using ATP showed a higher rate of RA 
triggers. Hasebe et al. (23) also used 20 mg of ATP after other methods of AF 
induction, including Iso, failed. More patients had RA triggers than PV triggers with 
ATP injection (6 vs. 4) and frequency analysis suggested the driver to reside in the 
RA during AF in those with RA triggers. These patients were younger and also more 
often had a family history of AF. The authors suggested they may have a distinct form 
of the arrhythmia, which they named RA fibrillation. However, it is possible that in 
Hasebe’s study (24), younger patients were more difficult to induce with other 
methods (including Iso) and therefore more likely to receive ATP or Ado. The higher 
rate of RA fibrillation in their case might be merely a manifestation of the preferential 
effect of ATP/Ado on the RA. (24) 
The high percentage of RA triggers seen with Ado/ATP may be related to the drug’s 
route of administration, short half-life and mode of action. Ado/ATP is administered 
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into a central vein or directly the RA, and therefore the concentration of the drug is 
higher in the RA than the LA, after having travelled through the lungs, where – due to 
its very short half-life – a great fraction may be eliminated. Moreover, the sensitivity 
of the RA to Ado is known to be higher than the LA (25, 26), explained by an at least 
two-fold higher expression of the Ado receptor in the RA (27). Receptor density in the 
RA has also been correlated to Ado-induced AF in humans (27). Although direct 
injection of adenosine into the LA had been proposed, this was not done in this study, 
due to concerns of air embolism (28).  
Relation between induced and spontaneous triggers 
Few studies have compared induced and spontaneous AF. Lazar et al. analyzed atrial 
activation frequency distribution and found no difference between patients with 
spontaneous AF (3 patients) and Iso-induced AF (13 patients) (29), while Calvo et al. 
showed the same for pacing induced AF (30). In the abovementioned study, Tao et al. 
(22) found that the spontaneous AF initiation site was in the PVs in 96% of cases, 
while after ATP injection in 85%. Only in one of the 4 patients with a non-PV trigger 
manifested by ATP was there a correlation with the spontaneous site. In other words, 
they show - similarly to our results - more non-PV triggers with ATP, compared with 
spontaneous AF, but the majority of those ATP-induced non-PV triggers were not 
clinical. We have seen 4 patients in whom Ado reproduced spontaneous AF, but none 
originated outside the PVs. Therefore, it seems that Ado/ATP may reproduce PV-
triggers; however, the frequent non-PV triggers seen with these drugs cannot be 
correlated with spontaneous AF. 
The question arises whether non-PV triggers induced by Ado are clinically relevant as 
initiators of spontaneous AF. Triggers of spontaneous AF in our and the above-
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mentioned reports (4,5,10) have been located to the PVs in more than 90% of the 
cases. The high percentage of non-PV AF-initiating sites seen with Ado is in sharp 
contrast with this observation.  
5. Limitations 
The study has several limitations. First, the localization of PV triggers was done with 
approximation because of the limited number of catheters in the LA and RA. 
However, differentiating LA from RA and PV from non-PV triggers is 
straightforward with this catheter setup. After the first drug induced AF, we frequently 
(33% after Iso and 22% after Ado) encountered immediate recurrence of AF after 
cardioversion preventing us to administer the second drug. Therefore, the number of 
patients who received both Iso and Ado is relatively low.  
6. Clinical implications 
The literature on non-PV triggers of AF relies heavily on the use of Ado/ATP for 
induction, although the correlation with spontaneous AF has never been established. 
We show in a comparison with Iso before PVI that Ado much more frequently 
induces non-PV triggers, especially from the RA. The clinical significance of these 
foci, however, remains questionable since Ado induced non-PV triggers in some 
patients who had PV-triggers with Iso, and the concordance of non-PV triggers with 
spontaneous AF could not be documented. Moreover, the induction of non-PV 
triggers by Ado before PVI did not influence the success of the procedure. Based on 
the above, Ado cannot be recommended for the identification of trigger sites to guide 
catheter ablation of paroxysmal AF. 
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Figure 1. Left anterior oblique (LAO) and right anterior oblique (RAO) view showing 
the two decapolar catheters placed in the coronary sinus (CS) and right atrium (RA), circular 
mapping catheter (CMC) in the left pulmonary veins (PVs) and mapping catheter (ABL) in 
right PVs. 
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Figure 2. Surface electrocardiogram lead I, II, V6 along with intracardiac recordings 
from right atrium (RA), coronary sinus (CS) and circular mapping catheter (CMC) placed in 
the pulmonary vein (PV) antrum, during initiation of atrial fibrillation. Panel (A) during 
adenosine infusion AF was induced from RA. Spontaneously (Panel B) and during 
isoproterenol infusion (Panel C) AF was induced from the PVs. Paper speed=75mm/s. 
During redo procedure only the previous triggering pulmonary vein was reconnected (Panel 
D). Paper speed=100mm/s.  
 
Figure 3. Trigger sites of isoproterenol induced AF (Panel A) and adenosine induced 
AF (Panel B). 
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Figure 4. Study flowchart. IRAF: immediate recurrence of atrial fibrillation (AF) after 
cardioversion, Ado: adenosine, Iso: isoproterenol, LPV: left pulmonary veins (PV), RPV: 
right PV, RA: right atrium, CS: coronary sinus. 
 
Table 1. Characteristics of patients who received both drugs. Abbreviations are as on 
Figure 4. 
Patient # First drug 
Isoproterenol Adenosine 
Spontaneous 
triggers 
Max. dose 
(µg/min) 
Induced 
triggers 
Max. dose 
(mg) 
Induced 
triggers 
1 Ado 10 LPV 18 RA - 
2 Ado 20 LPV 18 LPV LPV 
3 Iso 20 LPV 18 LPV - 
4 Iso 20 - 18 RA - 
5 Ado 20 - 18 RA - 
6 Ado 20 LPV 36 - - 
7 Ado 20 LPV 36 - - 
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8 Iso 5 LPV 36 CS - 
9 Ado 20 LPV 36 - - 
10 Iso 15 RPV 36 - RPV 
11 Iso 3 LPV 36 - LPV 
12 Iso 20 - 36 - - 
13 Ado 20 - 36 - - 
14 Iso 20 - 36 - - 
15 Ado 20 - 36 - LPV 
16 Ado 20 - 36 - - 
17 Ado 20 - 36 - - 
18 Ado 20 - 36 - - 
19 Iso 20 - 36 - - 
20 Iso 20 - 36 - - 
21 Iso 20 - 36 - - 
22 Ado 20 - 36 - - 
23 Iso 20 - 36 CS - 
24 Ado 20 - 36 - - 
25 Iso 20 - 36 RA - 
26 Ado 20 - 36 - - 
 
